MET and neoplasm: The finding that the combination of Plk1 and cMet inhibition led to striking tumor regression in vivo in both epithelial and mesenchymal NSCLC suggests that this combination would be broadly effective in NSCLC patients who may have tumors with heterogeneity or dynamic changes in EMT status.